Anzeige
Mehr »
Mittwoch, 14.01.2026 - Börsentäglich über 12.000 News
Gold auf Rekordhoch: Eine der spannendsten Gold-Stories 2026 steht ganz am Anfang
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
231 Leser
Artikel bewerten:
(1)

Amsterdam-based OLVG Lab adopts Vitestro's autonomous blood drawing devices

UTRECHT, Netherlands, April 12, 2023 /PRNewswire/ -- Amsterdam-based OLVG Lab, a leading Dutch clinical laboratory, will be the first European healthcare provider to introduce multiple autonomous blood drawing devices manufactured by Utrecht-based developer Vitestro. Both parties have signed an agreement for the acquisition of the devices, which will be installed once CE marking has been obtained. The innovation will contribute to safe, consistent blood drawing, as well as helping to solve the growing healthcare workforce shortage.

Signing of the acquisition agreement for the blood drawing device by OLVB Lab and Vitestro. From left to right Toon Overbeeke (CEO, Vitestro), Brian Joseph (Commercial director, Vitestro), Cees Buren (OLVG, Member Board of directors), Anja Leyte (Director, OLVG Lab)


This represents a significant next step in the cooperation between the two parties. OLVG Lab, along with several other Dutch laboratories, has been involved in the development of the autonomous blood drawing devices since 2018. Vitestro's innovative technology has been successfully tested with both patients and blood drawing staff at OLVG hospital. OLVG Lab continues to play a significant role in the introduction of this groundbreaking innovation.

Staff and patients enthusiastic
"Robotization has become an important topic in diagnostics. Vitestro's technology will improve the standardization and optimization of the sampling procedure. And it helps solve staff shortages in our blood drawing department", says Anja Leyte, director of OLVG Lab. "But more importantly, the patients are also very positive. Our staff are really enthusiastic as well and can't wait to start using this breakthrough technology in our healthcare."

In the coming period, a number of hospitals, laboratories and blood drawing departments will be preparing for the introduction of the blood drawing device. This is expected to take place in late 2024. As part of this, the first OLVG Lab staff have already participated in the Vitestro Academy. There they learn to use the new technology safely and how the work process is shaped by this development.

Success
The technology is intuitive. Patients can choose to have the device draw their blood for them and go through the blood draw completely independently under the supervision of a trained blood drawing staff member. This new way of taking blood will complement the usual form of blood sampling. The use of the devices should make up for the shortage of staff, allowing the busy blood collection clinic to be organized more efficiently.

"After more than 5 years of co-creation and development with OLVG Lab, this is a special moment", says Toon Overbeeke, co-founder and CEO of Vitestro. "It is a privilege to be the first to place our innovation at OLVG Lab. Together, we will make sure this innovation will become a great success for both employees and patients."

About OLVG Lab

OLVG Lab is one of the leading integrated laboratories in the Netherlands, providing services to hospitals (OLVG, BovenIJ, Flevoziekenhuis and Tergooi), clinics and primary care providers in the Greater Amsterdam area and Flevoland. Besides blood drawing, OLVG Lab provides clinical chemistry, medical microbiology and pathology services. Together with our partners, OLVG Lab offers a widespread, efficient network of blood collection centers in the region, including clinics at OLVG in Amsterdam East and West, ensuring that patients always have access to blood drawing facilities near their home.

About Vitestro

In 2017 Vitestro's founders rose to the challenge of creating a better blood drawing experience. Today Vitestro is well on the way to achieving its goal, with a committed team of around 50 highly skilled professionals experienced in medical robotics, imaging software, AI, QA/RA and business development. Vitestro is based in Utrecht, the Netherlands.

Please contact for more information:

Vitestro, Utrecht, the Netherlands
Toon Overbeeke, CEO and co-founder
T: +31 30 200 4551
E: publicrelations@vitestro.com
W: www.vitestro.com

OLVG Lab, Amsterdam, the Netherlands
Olderik Dijkstra
T : +31 6 212 47 759
E : o.dijkstra@olvg.nl
W: www.olvglab.nl

LifeSpring Life Sciences Communication
Leon Melens
T: +31 6 538 16 427
E: lmelens@lifespring.nl

Photo - https://mma.prnewswire.com/media/2052486/vitestro_OLVG.jpg
Logo - https://mma.prnewswire.com/media/2036806/3982008/Vitestro_Logo.jpg

Vitestro Logo

Cision View original content:https://www.prnewswire.co.uk/news-releases/amsterdam-based-olvg-lab-adopts-vitestros-autonomous-blood-drawing-devices-301795524.html

© 2023 PR Newswire
Gold & Silber auf Rekordjagd
Kaum eine Entwicklung war 2025 so eindrucksvoll wie der Höhenflug der Edelmetalle. Allen voran Silber: Angetrieben von einem strukturellen Angebotsdefizit, explodierte der Preis und übertrumpfte dabei den „großen Bruder“ Gold. Die Nachfrage aus dem Investmentsektor zieht weiter an, und ein Preisziel von 100 US-Dollar rückt in greifbare Nähe.

Auch Gold markierte neue Meilensteine. Mit dem Durchbruch über 3.000 und 4.000 US-Dollar pro Unze hat sich der übergeordnete Aufwärtstrend eindrucksvoll bestätigt. Rücksetzer bleiben möglich, doch der nächste Zielbereich bei 5.000 US-Dollar ist charttechnisch fest im Blick. Die fundamentalen Treiber sind intakt, eine nachhaltige Trendwende aktuell nicht in Sicht.

Für Anlegerinnen und Anleger bedeutet das: Jetzt ist die Zeit, um gezielt auf starke Produzenten zu setzen. In unserem neuen Spezialreport stellen wir fünf Gold- und Silberaktien vor, die trotz Rallye weiter attraktives Potenzial bieten, mit robusten Fundamentaldaten und starken Projekten in aussichtsreichen Regionen.

Jetzt den kostenlosen Report sichern und von der nächsten Welle im Edelmetall-Boom profitieren!

Dieses exklusive PDF ist nur für kurze Zeit verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.